Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Both the δDs of sea water and the fractionations associated with hyptophyte biochemistry (εbio) are fairly well understood, so alkenones can be readily used to observe the secondary effect of salinity on δD. There is a well established positive linear correlation between salinity and εl/w, on the order of a ~3‰ change in fractionation per salinity unit. Hypothesized mechanisms for this effect include enrichment of D in intracellular water due to reduced exchange with extracellular water at higher salinity, removal of H from intracellular water due to increased production of solutes to maintain osmotic pressure at higher salinity, and lower haptophyte growth rates at higher salinity Alkenone δDs have been used successfully to reconstruct past salinity changes in the Mediterranean Sea, Black Sea, Panama Basin, and Mozambique Channel. As an extension of salinity, this data was also used to draw further conclusions about ancient environments, such as ancient freshwater flooding events, and the evolution of plankton in response to environmental changes
An urgent issue that had to be addressed was the economic crisis that began in 1974. Minister of Economy Fuentes Quintana proposed the signing of a great "social pact" that would "compensate" the harsh adjustment measures that had to be taken through social improvements and some juridical-political reforms. This led to the Moncloa Pacts signed on October 27, 1977, which succeeded in stabilizing the economy and controlling inflation ─ from 26.4% in 1977 to 16.5 the following year ─ and social spending was increased in return ─ unemployment benefits, pensions, education and health spending ─ thanks to the tax reform implemented by Minister Francisco Fernández Ordóñez. Another pressing matter was the "regional question", since the demands for self-government on the part of Catalonia and the Basque Country did not admit any further delay. In the case of Catalonia, the restoration of the Statute of Autonomy approved by the Republic was demanded, but Suárez opted to approve a decree-law of September 29, 1977, which "provisionally" restored the Generalitat although without reference to the 1932 Statute which allowed the return from exile of the "president" Josep Tarradellas. For the Basque Country, the Basque General Council was constituted in December 1977 under the presidency of the socialist Ramón Rubial, but as in the case of Catalonia, the Statute of Autonomy approved by the Republic was not reestablished either.
== Products and services == GeneDx offers genetic testing services with a primary focus on whole genome sequencing (WGS) and whole exome sequencing (WES). WGS provides a comprehensive analysis of an individual's entire genome, while WES focuses on protein-coding regions called exons, which contain a majority of known disease-related genetic variants. The company's tests are used in clinical diagnostics, research, and precision medicine by geneticists, genetic counselors, neonatologists, pediatric specialists, and pediatricians. GeneDx offers testing for conditions including rare diseases, autism spectrum disorders, epilepsy, neurodevelopmental disorders, cardiomyopathies, and inherited conditions affecting vision, the immune system, muscles, hearing, metabolism, neurology, and mitochondrial diseases. GeneDx also offers rapid sequencing options intended for critically ill pediatric and neonatal patients where timely results may influence acute medical management. GeneDx continues to develop genetic testing technologies and expand access to genomic information for clinical use in pediatric, adult, and newborn populations. Professional guidelines from organizations such as the American College of Medical Genetics and Genomics (ACMG) and the American Academy of Pediatrics (AAP) support the use of exome or genome sequencing as first-line or early diagnostic tests in selected patient populations.
Sources: en.wikipedia.org
=== Other characters === Toko Miura as Chiyoko Shimakura, a singer whose career becomes connected to Kazuko and Hotta. Yuko Nakamura as Mirei Sei, a fortune teller who influences Kazuko's later career. Shingo Mizusawa as a street vendor (episode 1). Hiccorohee as Mai (episode 1). Kimiko Yo as Kiyo Mita (episodes 2–3), Marohiko's mother and the head of the Mita household. Miwako Ichikawa as Towako Kato (episodes 8–9), Masataka Yasunaga's daughter. Show Kasamatsu as Osamu Miyazawa, Minori Uozumi's ex-husband (episode 8). Kaho Tsuchimura as a mistress (episodes 8–9). Toshie Negishi as Minori Uozumi's mother. Nagomu Miyamoto as Nobu Murao. Razor Ramon HG as himself
== Technology == Aroa Biosurgery develops medical devices using its proprietary ovine forestomach matrix (OFM) technology. OFM is a layer of decellularized extracellular matrix (ECM) biomaterial isolated from the propria submucosa of the rumen of sheep. OFM is used in tissue engineering and as a tissue scaffold for wound healing and surgical applications.
Magic numbers of 2, 8, 20, 28, 50, 82 and 126 have been observed for neutrons, and the next number is predicted to be 184. Protons share the first six of these magic numbers, and 126 has been predicted as a magic proton number since the 1940s. Nuclides with a magic number of each—such as 16O (Z = 8, N = 8), 132Sn (Z = 50, N = 82), and 208Pb (Z = 82, N = 126)—are referred to as "doubly magic" and are more stable than nearby nuclides as a result of greater binding energies. In the late 1960s, more sophisticated shell models were formulated by American physicist William Myers and Polish physicist Władysław Świątecki, and independently by German physicist Heiner Meldner (1939–2019). With these models, taking into account Coulomb repulsion, Meldner predicted that the next proton magic number may be 114 instead of 126. Myers and Świątecki appear to have coined the term "island of stability", and American chemist Glenn Seaborg, later a discoverer of many of the superheavy elements, quickly adopted the term and promoted it. Myers and Świątecki also proposed that some superheavy nuclei would be longer-lived as a consequence of higher fission barriers. Further improvements in the nuclear shell model by Soviet physicist Vilen Strutinsky led to the emergence of the macroscopic–microscopic method, a nuclear mass model that takes into consideration both smooth trends characteristic of the liquid-drop model and local fluctuations such as shell effects.
Sources: en.wikipedia.org
==== Sleep disorders ==== Modafinil, a eugeroic or wakefulness-promoting drug, is used for treating narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. Being a central nervous system (CNS) stimulant itself, modafinil has lower addictive potential than classical stimulants such as amphetamine, cocaine, or methylphenidate, but still produces psychoactive and subjective effects typical of classical stimulants. Narcolepsy causes a strong urge to sleep during the day and can include symptoms like cataplexy (sudden muscle weakness), sleep paralysis (inability to move or speak while falling asleep or waking up), and hallucinations. Narcolepsy is linked to a lack of the brain chemical hypocretin (orexin), primarily produced in the hypothalamus. Modafinil is not a cure for narcolepsy, but it can help manage the symptoms. While modafinil is used to treat excessive sleepiness, it may also help reduce the frequency and severity of cataplexy attacks in some people. Modafinil is approved for management of narcolepsy with or without cataplexy. However, it is not specifically approved for the treatment of cataplexy. Modafinil is also prescribed for shift work sleep disorder, a condition affecting people who work rotating or night shifts and experience excessive sleepiness during work hours and difficulty sleeping during the day. The recommended dose for this indication is 200 mg taken approximately one hour before the start of the work shift.
=== 10 March === The SAF claimed to have destroyed 47 vehicles and 100 drones belonging to the RSF in El Fasher over the course of 10 days. They also claimed that local forces killed 15 fighters and that they recaptured the whole Al-Salam neighborhood and the Lafat Taqro buildings in the south of the city.
== Involvement with other quality associations == RQA regulatory collaborates with its US counterpart SQA and attends SQA's annual meeting along with running a global conference every three years with both Society of Quality Assurance and Japan Society of Quality Assurance. A European Conference is also held every three years with the French association SoFAq and the Germany association DGGF. The association also has a memorandum of understanding with JSQA (Japan), SQA (USA), GQMA (Germany), SoFAq (France) and SARQA (Sweden).
=== Alkene === Alkenes rarely need protection or are protected. They are as a rule only involved in undesired side reactions with electrophilic attack, isomerization or catalytic hydration. For alkenes two protecting groups are basically known:
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.